The Dietary Supplement EGCG: NOPE (N-Oleyl-Phosphatidylethanolamine and Epigallocatechin-3-Gallato Formula) Helps Patients to Follow a Flexible Dietary Regimen and Induces Loss of Weight in Patients who had Previously Experienced No Response to Other Weight Loss Intervention

Daniele Barbaro*, Anna Menasci, Barbara Baldini, Cristina Pasquini and Paola Lapi
Section of Endocrinology, ASL6 Livorno, Italy

Abstract
Background and aims: Obesity is increasing in all countries. The aim of this study was that of evaluating if the treatment with the dietary supplement (N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallato formula, EGCG-NOPE) could help patients to follow a flexible dietary regimen.

Methods: 38 patients (20 males, 18 females, BMI 32-41, aged 33-72 years) were enrolled consecutively. These patients were subjects who had experienced no loss of weight during an intervention program consisting of a short training period, aimed at behaviour modification, followed by a dietary program based on rules of diet, without a fixed amount of calories. These patients were instructed to take EGCG-NOPE, two capsules (EGCG 120 mg and NOPE 170 mg each capsule) at 1 hour before lunch and dinner, for two months. The study had a crossover design, and after two months EGCG-NOPE was stopped, the patients continuing to follow only the prescribed dietary rules. After a further two months, patients again took EGCG-NOPE for two more months. The primary end-point of the study was weight loss and a decrease in hip circumference, while the secondary end-point involved metabolic parameters: serum glucose, Homeostasis Model Assessment (HOMA) index, serum LDL and HDL cholesterol and triglycerides.

Results: After two months of treatment with EGCG-NOPE, the weight loss was 2.42 kg (p<0.001), and the decrease in hip circumferences was 2.0 cm (p<0.001). There was also a decrease in serum glucose (0.083 mmol/L, p<0.001), HOMA index (0.48 p<0.001), serum LDL cholesterol (0.46 mmol/L, p<0.01), and serum triglycerides (0.25 mmol/L, p<0.001). HDL cholesterol increased by 0.20 mmol/L (p<0.01). Following the two months without treatment, the weight and hip circumference were steady. After the next two months of treatment, the patients had a further loss of weight (2.10 kg (p<0.01) and a further decrease in hip circumference (2.0 cm (p<0.001).

Conclusions: EGCG-NOPE, at these doses, has shown that it is capable of decreasing the body weight and hip circumferences in patients who had failed to lose weight during a previous dietary regimen. The improvement in the metabolic parameters during treatment with EGCG-NOPE represents a further aspect of paramount importance.

Keywords: EGCG-NOPE; HOMA index; Dietary supplement

Introduction
Obesity is increasing in all countries, and represents one of the most concerning problems of public health. Lifestyle modification is the cornerstone of the treatment of obesity, but the short- and long-term effects of conventional weight-loss programs are often unsatisfactory. For this reason, there is an increasing demand for pharmaceutical treatment of this condition [1-4]. Decreasing nutrient absorption, inhibition of appetite and increasing thermogenesis are possible pharmacological methods of treatment. However, most of these have important drawbacks: decreasing nutrients may cause gastrointestinal discomfort, while inhibition of appetite usually involves action effecting the brain structure, with important side effects [5]. To date, no safe drug inhibiting the appetite or increasing thermogenesis is available. For these reasons, there is now great interest in dietary supplements and there are some important papers showing that green tea catechins can have beneficial effects on weight loss and can improve some metabolic abnormalities in obese subjects.

Recently, a dietary supplement made up of two natural active substances, epigallocatechin3-gallate (EGCG) and N-oleyl-phosphatidylethanolamine (NOPE), has been developed and marketed, and EGCG-NOPE has been shown to be capable of improving compliance with a low-energy diet [6]. A recent randomized double-blind study has shown that the intake of EGCG-NOPE complex improved compliance with diet in a group of healthy overweight or obese patients. All patients treated with EGCG-NOPE experienced an increased feeling of fullness, less severe binge eating, and fewer depressive symptoms during a weight-reduction program based on a restriction of daily energy intake of 3344kJ/d calories less than the daily requirements according to WHO criteria [6]. However, the problem of long-term compliance is not only related to a feeling of well-being...
in patients, but also to the difficulty of maintaining a diet with a fixed number of calories, as well as many patients being bothered by having to weigh foods and adhere to fixed recipes.

For this reason, the aim of this study was not that of evaluating patients who were obliged to follow a predetermined low-calorie diet, but patients freely eating what they wanted, and only following dietary rules after a short training period regarding types of foods and lifestyle.

Patients, Methods, and Design of the Study

The study was approved by the Ethics Committee of our hospital and thirty-eight patients were consecutively enrolled: 20 males (aged 39-67 years, BMI 33-41) and 18 females (aged 39-72 years, BMI 32-40). Enrolled patients were subjects who had experienced no loss of weight during multiple previous treatments by “herbal” and/or other dietary supplement associated to dietary weight reduction program based on a restriction of daily calories. Moreover all these patients had experienced no loss of weight (or a loss of weight < 0.5 kg/month) during our program intervention consisting of a short training period aimed at behaviour modification, and a further short training period regarding types of food, followed by a dietary program based on rules of diet without a fixed amount of calories (see Table 1). General rules concerning lifestyle were also imparted. Patients were followed weekly for the first month, and then monthly, to evaluate adherence to the dietary program. The 38 patients who had failed to show weight loss, as described above, represented 31% of all patients seen over a one-month period. Regarding these patients, an analysis of their dietary diary revealed that 32 of the 38 exhibited a clear non-adherence to the regimen prescribed. For the remaining 6 patients, there was, apparently, no clear explanation regarding their failure to lose weight, since they reported to have followed the dietary regimen. All subjects, after giving their written consent, were invited to take EGCC-NOPE (EGCC 120 mg and NOPE 170 mg each capsule). 2 capsules at 1 hour before lunch and dinner, while continuing with the same intervention program. The study had a cross-over design, and after two months EGCC-NOPE was stopped, with patients only continuing to follow the prescribed dietary rules. After a further two months, patients again took EGCC-NOPE as before. The primary end-point of the study was weight loss and decrease of hip circumference, while the secondary target involved metabolic parameters: blood glucose, Homeostasis Model Assessment (HOMA) index, serum LDL and HDL cholesterol, and triglycerides. Weight loss was assessed at the beginning of the study and then after two, four, and six months (see Figure 1). HOMA index was calculated, following the literature, as

\[
\text{HOMA} = \frac{\text{fasting plasma insulin (microU/ml)} \times \text{fasting blood glucose (mmol/L)}}{22.5}
\]

Variation of anthropometric variables and variation of metabolic parameters are summarized in Table 2. No patients experienced adverse side effects.

Results

After two months of treatment with EGCC-NOPE, the weight loss was 2.42 kg +/- 0.3 kg (p<0.001), and the decrease in hip circumference was 2.0 cm +/- 0.2 cm (p<0.001). There was a decrease in serum glucose of 0.83 +/- 0.06 mm/L (p<0.001), a decrease in the HOMA index of 0.48 +/- 0.03 (p<0.001), serum LDL cholesterol decreased by 0.45 +/- 0.04 mm/L (p<0.01), serum HDL cholesterol increased by 0.20 +/- 0.01 mm/L (p<0.01), and triglycerides was reduced by 1.14 +/- 0.20 mm/L (p<0.001). No side effects were reported, and patients experienced a greater ability to follow the dietary regimen. Following the two months without treatment, the weight and metabolic parameters were steady, apart from the HOMA index, which increased by 0.20 +/- 0.01 (p<0.01). After the next two months of treatment, the patients had a further weight loss of 2.10 +/- 0.2 kg (p<0.001), with a further reduction in the HOMA index of 0.42 +/- 0.03 (p<0.001), and a further reduction in triglycerides of 0.25 +/- 0.03 mm/L (p<0.001). No statistical variation was shown for serum glucose or LDL and HDL cholesterol. Clinical data at the various stages are plotted in Figures 1 and 2. Also plotted in Figures 1 and 2 are clinical data of the subgroup of patients who reported to have carefully kept to the dietary regimen and lifestyle modifications. The metabolic parameters are summarized in Table 2.

![Figure 1: Loss of weight in patients (difference in respect to the previous value, reported as mean). Dark line: all patients. Bright line: subgroup of patients (n=6) who appeared to have followed the dietary rules.](image)

<table>
<thead>
<tr>
<th>Five Meals A Day: 3 Main Meals And Two Snacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lunch and Dinner:</td>
</tr>
<tr>
<td>Either bread or pasta, in moderate amounts, plus a second course: fish at least 5 times weekly; for the remaining courses always choose lean meat or chicken breast, and twice a week soft, low-fat cheese (see the tag, or choose buttermilk curd).</td>
</tr>
<tr>
<td>Vegetables every day, two servings of fruit after each meal, avoiding grapes, figs, persimmon, and bananas.</td>
</tr>
<tr>
<td>Snacks:</td>
</tr>
<tr>
<td>One yoghurt or a piece of fruit or a glass of milk.</td>
</tr>
<tr>
<td>Condiments:</td>
</tr>
<tr>
<td>Put 130 g of extra-virgin olive oil in a bottle, and use, as much as possible, this oil both for cooking and for seasoning. Prefer steam cooking or on an iron plate.</td>
</tr>
<tr>
<td>As much as possible, eliminate cakes, salami, and sausages. No cheese, apart from as stated above.</td>
</tr>
<tr>
<td>Drinks:</td>
</tr>
<tr>
<td>Abundant water, one glass of wine or one &quot;medium-size beer&quot; per day. No hard alcoholic beverages. No fruit juice.</td>
</tr>
</tbody>
</table>

Table 1: Rules of diet given to the patients. All the options were explained in detail.


Table 1: Rules of diet given to the patients. All the options were explained in detail.
The dietary supplement EGCG: NOPE (N-Oleyl-Phosphatidylethanolamine and Epigallocatechin-3-Gallato Formula) Helps Patients to Follow a Flexible Dietary Regimen and Induces Loss of Weight in Patients who had Previously Experienced No Response to Other Weight Loss Intervention. J Obes Weig los Ther 1:105. doi:10.4172/2165-7904.1000105

Discussion

In any long-term diet, compliance of the patients represents the crucial point for the successful treatment of obesity. A failure in compliance by patients with the dietary regimen may be related to a reduced feeling of well-being, to severe binge eating, or to mood depression. Moreover, a fixed hypocaloric diet can produce a paradoxical effect on the appetite, resulting in compulsive hunger. All these aspects are often worsened by the objective difficulty of cooking fixed recipes with a fixed amount of calories [1-4,7,8].

For these reasons, our approach, in patients supposed to be capable of changing their dietary behaviour, is usually to impart training regarding the types of foods, followed by dietary rules without any fixed daily caloric intake. Among a group of patients who were subjects in this program, but who were unable to lose weight, we investigated the effect of EGCG-NOPE. Since the literature reports the use of green tea catechins till to 1000 mg daily [20-24] we decided to use ECGC-NOPE and Epigallocatechin-3-Gallate, and to go on with a lower dose of EGCG-NOPE in the following study [16,18,19]. It is impossible to say if our results are merely due to the effects of EGCG-NOPE on satiety, or are also due to a direct effect of prevention of body fat accumulation, or to some lipolytic action. The fact that a small subgroup of patients, in which there was evidence of adherence to a dietary and lifestyle regimen, showed a loss of fat only after treatment with EGCG-NOPE could theoretically support the hypothesis of a direct effect on fat accumulation by this compound, at least as regards the doses used in this study.

In a previous study, the beneficial effect of EGCG-NOPE on body weight had already been demonstrated. In that double-blind randomized study, EGCG-NOPE was shown capable of inducing satiety, of decreasing binge eating, and of ameliorating mood compared against a placebo. Treated patients demonstrated an improved sense of well-being during a fixed-diet, energy-restriction regimen of 3344 kJ/d, with the conclusion of the study being that EGCG-NOPE could increase compliance with the diet. In this study, a half dose of EGCG-NOPE was used, and the loss of weight recorded was not statistically different between the two groups.

Our study allowed us to demonstrate that EGCG-NOPE can be effective even without prescribing a fixed hypocaloric diet, and this can be a great advantage for a long-term dietary regimen. We investigated neither binge eating severity nor depressive symptoms because all patients had already failed the previous dietary regimen and the fact that EGCG-NOPE induced weight loss is the best evidence indicating the improved well-being of these subjects. As already stated, a further effect could, of course, be a direct action of this compound, at these doses, on fat accumulation.

Another important action of EGCG-NOPE could be, as shown in the already-quoted study, the effect of EGCG on insulin sensitivity as much as it is well documented that catechins improve insulin action. Our study corroborate this, and, in fact, the results suggest that the effects on insulin resistance are not merely due to the loss of weight, but appear to be related to a direct effect of EGCG-NOPE on insulin sensitivity. Our study was not a blind study and for this reason we can’t completely rule out a placebo effect of the capsules of EGCG-NOPE. However this hypothesis, in our opinion, appears remote because all these patients were enrolled because they had previously experienced multiple failures during ingestion of herbal or dietary supplement. So, we can suppose that in our group placebo effect was negligible. Moreover the modifications of HOMA index have appeared to be not different between the two groups.

Table 2: Data regarding metabolic parameters. Data are reported as the difference from the previous value and expressed as mean +/- ES.

<table>
<thead>
<tr>
<th></th>
<th>Two months</th>
<th>Four months</th>
<th>Six months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum glucose mm/L</td>
<td>-0.83 +/- 0.06</td>
<td>+0.11 +/- 0.005</td>
<td>-0.17 +/- 0.02</td>
</tr>
<tr>
<td>HOMA Index</td>
<td>-0.48 +/- 0.03</td>
<td>+0.20 +/- 0.01</td>
<td>-0.42 +/- 0.03</td>
</tr>
<tr>
<td>LDL-cholesterol mm/L</td>
<td>-0.45 +/- 0.04</td>
<td>+0.06 +/- 0.005</td>
<td>-0.03 +/- 0.007</td>
</tr>
<tr>
<td>HDL-cholesterol mm/L</td>
<td>+0.20 +/- 0.01</td>
<td>+0.025 +/- 0.0005</td>
<td>-0.01 +/- 0.0025</td>
</tr>
<tr>
<td>Tryglicerides mm/L</td>
<td>-1.14 +/- 0.10</td>
<td>-0.045 +/- 0.0006</td>
<td>-0.25 +/- 0.03</td>
</tr>
</tbody>
</table>

\( p \) = N.S.

Figure 2: Decrease in hip circumference (difference in respect to the previous value, reported as mean). Dark line: all patients. Bright line: subgroup of patients (n=6) who appeared to have followed the dietary rules.
Our results regarding metabolic parameters have shown not only an improvement in the HOMA index, but also an improvement in lipid profiles. Insulin resistance and the "low grade" inflammatory status, which are usually strongly related, can affect serum lipids, and can especially increase LDL cholesterol and decrease HDL cholesterol. Our study doesn’t permit us to say if the effect on lipids is a result of direct action on the lipids or is a secondary effect coming from the decrease in insulin resistance, but, without doubt, the improvement in the metabolic parameters represents primary benefits for obese patients.

Conclusions

EGCG-NOPE appears to bring about several beneficial effects in obese patients. Using fixed doses of EGCG-NOPE (EGCG 480 mg/day and NOPE 680 mg/day), our study has shown that patients can lose weight when treated employing a flexible dietary regimen, and this may represent a great benefit for those subjects who, for various reasons, exhibit a low degree of compliance with fixed hypocaloric diets. During the two months of stoppage of the treatment, weight remained steady, and this appears to be another important datum; moreover, the improvement seen in metabolic profile during the intake of EGCG-NOPE represents a further aspect of paramount importance for obese patients. Whether treatment with EGCG-NOPE can be continued safely, over long periods, and whether it can induce a progressive loss of weight when optimal weight has been achieved, is something to be established by long-term study.

References